A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration

2007 ◽  
Vol 28 (3) ◽  
pp. 187-192 ◽  
Author(s):  
Amelia E.B. Moore ◽  
Glen M. Blake ◽  
Ignac Fogelman
2020 ◽  
Vol 75 (6) ◽  
pp. 1554-1558 ◽  
Author(s):  
E Leegwater ◽  
B V C Kraaijenbrink ◽  
D J A R Moes ◽  
I M Purmer ◽  
E B Wilms

Abstract Objectives To describe the population pharmacokinetics and protein-binding characteristics of unbound ceftriaxone administered as continuous or intermittent infusion. Additionally, to determine the optimal dosing regimen in critically ill patients. Methods A pharmacokinetic study was performed in the ICU of a tertiary teaching hospital. Patients were treated with ceftriaxone as continuous or intermittent infusion. A population pharmacokinetic model was developed with non-linear mixed-effects analysis. Subsequently, the PTA of a 100% T>MIC was assessed for influential patient characteristics using Monte Carlo simulation. Results Fifty-five patients were included. The pharmacokinetics of ceftriaxone was best described by a one-compartment model with non-linear saturable protein binding including the following covariates: body weight, estimated CLCR, serum albumin concentration and mode of administration. For pathogens with an MIC of 1 mg/L, the simulation demonstrated that intermittent infusion of 2 g/24 h only resulted in a ≥90% PTA in patients with a reduced CLCR (0–60 mL/min). Intermittent infusion of 2 g/12 h led to sufficient exposure if CLCR was 0–90 mL/min and continuous infusion of 2 g/24 h led to a ≥90% PTA in all simulations (CLCR 0–180 mL/min). Conclusions In the critically ill, the clearance of unbound ceftriaxone is closely related to CLCR. Furthermore, ceftriaxone protein binding is saturable, variable and dependent on serum albumin concentration. Intermittent dosing of 2 g/24 h ceftriaxone leads to subtherapeutic exposure in patients with a normal or increased CLCR. Treating these patients with continuous infusion of 2 g/24 h is more effective than an intermittent dosing regimen of 2 g/12 h.


2019 ◽  
Vol 28 (5) ◽  
pp. 401-409 ◽  
Author(s):  
Setor K. Kunutsor ◽  
Ari Voutilainen ◽  
Michael R. Whitehouse ◽  
Samuel Seidu ◽  
Jussi Kauhanen ◽  
...  

Objective: Low serum albumin concentration is associated with poor health outcomes, but its relationship with the risk of fractures has not been reliably quantified. We aimed to assess the prospective association of serum albumin with the risk of fractures in a general population. Subjects and Methods: Baseline serum albumin concentrations were measured in 2,245 men aged 42–61 years in the Kuopio Is­chemic Heart Disease study. Hazard ratios (HRs) (95% confidence intervals) were calculated for incident fractures. Results: A total of 121 fractures (hip, humeral, or wrist) were recorded during a median follow-up of 25.6 years. The risk of fractures increased linearly below a serum albumin concentration of ∼48 g/L. The age-adjusted HR (95% CI) for fractures per 1 standard deviation lower serum albumin was 1.24 (1.05–1.48). On further adjustment for several conventional and emerging risk factors, the HR was attenuated to 1.21 (1.01–1.45). Comparing the bottom versus top quartile of serum albumin levels, the corresponding adjusted HRs were 2.48 (1.37–4.48) and 2.26 (1.23–4.14). The association of serum albumin with fracture risk did not differ substantially according to age, body mass index, blood pressure, physical activity, alcohol consumption, socioeconomic status, inflammation, prevalent diseases, and smoking. Serum albumin at a threshold of 41.5 g/L demonstrated an area under the curve of 0.5850. Conclusion: In middle-aged Caucasian men, low serum albumin is associated with an increased risk of future fractures. The potential relevance of serum albumin concentrations in fracture prevention and prediction deserves further evaluation.


2008 ◽  
Vol 18 (4) ◽  
pp. 323-331 ◽  
Author(s):  
George A. Kaysen ◽  
Kirsten L. Johansen ◽  
Su-Chun Cheng ◽  
Chengshi Jin ◽  
Glenn M. Chertow

2019 ◽  
Vol 125 ◽  
pp. 184-192 ◽  
Author(s):  
Mario P. Smuts ◽  
Sonya de Bruyn ◽  
Peter N. Thompson ◽  
Dietmar E. Holm

2020 ◽  
Vol 55 (12) ◽  
pp. 2625-2629
Author(s):  
Shazia P. Sharif ◽  
Florian Friedmacher ◽  
Amir Amin ◽  
Rafdzah A. Zaki ◽  
Michael F. Hird ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document